Results 21 to 30 of about 21,799 (237)

What do oncologists need to know about biosimilar products?

Chinese Journal of Cancer, 2016
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.
Linda K. S. Leung, Kevin Mok, Calvin Liu, Stephen L. Chan   +3 more
doaj   +1 more source

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Key drivers for market penetration of biosimilars in Europe

Journal of Market Access & Health Policy, 2017
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available ...
Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi   +5 more
doaj   +1 more source

Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines [PDF]

, 2018
Objective: The aim was to critically evaluate well-established regulatory agencies mAb biosimilar guidelines for development and marketing authorization about quality, efficacy and safety and compare to BRICS-TM regulations to identify challenges ...
Anvisa, Castaneda-Hernandez, CBER, CBER, CBER, CBER, CBER, CBER, CBER, CDSCO, CFDA, Christl, Cofepris, Gautam, Lozda, MCC, Minghetti, Olech, Priori, Rushvi, Schiestl   +20 more
core   +5 more sources

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Терапевтический архив, 2021
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov   +7 more
doaj   +1 more source

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study

Biomedicines, 2022
This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness.
Martina Burlando, Gabriella Fabbrocini, Claudio Marasca, Paolo Dapavo, Andrea Chiricozzi, Dalma Malvaso, Valentina Dini, Anna Campanati, Annamaria Offidani, Annunziata Dattola, Raffaele Dante Caposiena Caro, Luca Bianchi, Marina Venturini, Paolo Gisondi, Claudio Guarneri, Giovanna Malara, Caterina Trifirò, Piergiorigio Malagoli, Maria Concetta Fargnoli, Stefano Piaserico, Luca Carmisciano, Riccardo Castelli, Aurora Parodi   +22 more
doaj   +1 more source

Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]

, 2020
The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core  

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]

, 2019
PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia, Bohlke, Kari, Castelli, Roberto, Djulbegovic, Benjamin, Lazo-Langner, Alejandro, Lustberg, Maryam B, Martino, Massimo, Mountzios, Giannis, Peswani, Namrata, Porter, Laura, Tanaka, Tiffany N., Trifirò, Gianluca, Yang, Hushan   +12 more
core   +3 more sources

Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies

Drug Metabolism and Pharmacokinetics, 2019
The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Akiko, Ishii-Watabe, Takashi, Kuwabara
openaire   +2 more sources

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources